Two Drugs Safe for Rare Forms of Kidney Cancer

(HealthDay News) --
Using a combination of the drugs temsirolimus (Torisel) and Bryostatin appears
to be safe in patients with metastatic kidney cancer, according to early data
from 25 patients in a phase 1 trial.

The researchers said a pathway known as mTOR signaling promotes tumor cell
proliferation and tumor blood vessel development. The temsirolimus-bryostatin
combination blocks two portions of the mTOR signaling pathway, and the early
data suggests the drugs may be active in patients with rare forms of renal cell
cancer that are less likely to respond to other therapies.

"We have certainly seen sustained responses with this combination, which
are encouraging," Dr. Elizabeth Plimack, a medical oncologist and attending
physician at Fox Chase Cancer Center in Philadelphia, said in a news release
from the center.

"Patients with non-clear cell renal cell cancer, including papillary renal
cancer, don't respond as well to tyrosine kinase inhibitors, such as sunitinib [Sutent]
and sorafenib [Nexavar], as patients with clear cell renal cell. So there is an
unmet need for therapy for these patients. We've seen that this combination may
be active to some degree for them," Plimack said.

The findings were to be presented Sunday at the American Society of Clinical
Oncology annual meeting, in Orlando, Fla. Read more…